Donna Carr

Biochemistry, Genetics and Molecular Biology · Life Sciences

17h-index2.8kcitations42works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Melanoma and MAPK Pathways(18), Synthesis and biological activity(11), Protein Kinase Regulation and GTPase Signaling(8), Cancer Mechanisms and Therapy(6), Hepatitis C virus research(5)

Publications42 total

Supplementary Figures from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Data from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Supplementary Figure Legends from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Supplementary Figure Legends from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Data from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Supplementary Figures from Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
2023Open Access
Development of a fully automated platform for agar-based measurement of viable bacterial growth
SLAS TECHNOLOGY·2022· 6 citedOpen Access
In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant <i>Pseudomonas Aeruginosa</i>
Open Forum Infectious Diseases·2020· 3 citedOpen Access
A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam
International Journal of Infectious Diseases·2019· 47 citedOpen Access
<i>In Vitro</i> Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A
Antimicrobial Agents and Chemotherapy·2018· 6 citedOpen Access
Structure-based drug design of clinical compound MK-8353, a novel inhibitor of ERK
Acta Crystallographica Section A Foundations and Advances·2018Open Access
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
ACS Medicinal Chemistry Letters·2018· 49 citedOpen Access
Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
2018
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology
Bioorganic & Medicinal Chemistry Letters·2018· 14 citedOpen Access
Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions
Journal of Medicinal Chemistry·2018· 13 cited
Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model
Antimicrobial Agents and Chemotherapy·2018· 61 citedOpen Access
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors
JCI Insight·2018· 145 citedOpen Access
Affinity Selection–Mass Spectrometry Identifies a Novel Antibacterial RNA Polymerase Inhibitor
ACS Chemical Biology·2017· 17 citedOpen Access
Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms
Journal of Medicinal Chemistry·2016· 47 cited
Structure–activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors
Bioorganic & Medicinal Chemistry Letters·2016· 16 cited
page 1 of 3Next →

Frequent Co-authors

Paul T. Kirschmeier(25), W. Robert Bishop(18), William T. Windsor(15), Gerald W. Shipps(15), Ahmed A. Samatar(15), Priya Dayananth(14), Alan Hruza(13), Ronald J. Doll(13), Jagdish Desai(12), Sunil Paliwal(11), Alan Cooper(9), Rumin Zhang(9), Linda James(9), Hugh Zhu(8), Erick J. Morris(7), Sharda Jha(7), Clifford R. Restaino(7), Yongi Deng(7), Stuart Black(7), Brian J. Long(7)